Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metoprolol succinate + felodipine is a fixed-dose oral combination of two antihypertensive agents used to treat high blood pressure. Metoprolol succinate is a beta1-selective adrenergic receptor blocker (beta-blocker) that reduces heart rate and cardiac output by antagonizing beta1-adrenoceptors in the heart, leading to decreased blood pressure and reduced myocardial oxygen demand[5][8]. Felodipine is a long-acting dihydropyridine calcium channel blocker that inhibits L-type calcium channels in vascular smooth muscle, resulting in vasodilation and decreased peripheral resistance[6]. The combination provides additive antihypertensive effects by targeting both cardiac output and vascular tone, offering improved blood pressure control compared to either agent alone without compromising tolerability[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metoprolol succinate + felodipine.